Intranasal IFNγ extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection
Author(s) -
Reljic R.,
Clark S.O.,
Williams A.,
FaleroDiaz G.,
Singh M.,
Challacombe S.,
Marsh P.D.,
Ivanyi J.
Publication year - 2006
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.2006.03012.x
Subject(s) - immunology , tuberculosis , mycobacterium tuberculosis , lung , nasal administration , medicine , antigen , antibody , monoclonal antibody , interferon gamma , biology , immune system , pathology
Summary Intranasal inoculation of mice with monoclonal IgA against the α‐crystallin (acr1) antigen can diminish the tuberculous infection in the lungs. As this effect has been observed only over a short‐term, we investigated if it could be extended by inoculation of IFNγ 3 days before infection, and further coinoculations with IgA, at 2 h before and 2 and 7 days after aerosol infection with Mycobacterium tuberculosis H37Rv. This treatment reduced the lung infection at 4 weeks more than either IgA or IFNγ alone (i.e. 17‐fold, from 4·2 × 10 7 to 2·5 × 10 6 CFU, P = 0·006), accompanied also by lower granulomatous infiltration of the lungs. IFNγ added prior to infection of mouse peritoneal macrophages with IgA‐opsonized bacilli resulted in a synergistic increase of nitric oxide and TNFα production and a 2–3 fold decrease in bacterial counts. Our improved results suggest, that combined treatment with IFNγ and IgA could be developed towards prophylactic treatment of AIDS patients, or as an adjunct to chemotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom